What is the best treatment for off‑phase dyskinesia in Parkinson disease?

Best Treatment for Off-Phase Dyskinesia in Parkinson's Disease

I need to clarify an important clinical distinction: "off-phase dyskinesia" is extremely rare in Parkinson's disease—the question likely refers to either OFF-time symptoms (bradykinesia, rigidity) OR on-phase dyskinesia (levodopa-induced dyskinesia). Since the context mentions dyskinesia specifically, I will address treatment of levodopa-induced dyskinesia, which occurs during ON-time, not OFF-time.

Treatment of Levodopa-Induced Dyskinesia

For patients with troublesome dyskinesia in advanced Parkinson's disease, GPi-DBS (globus pallidus interna deep brain stimulation) is the most effective intervention, followed by amantadine extended-release as the top oral medication option. 1

Invasive Therapies (First-Line for Advanced Disease)

The 2024 EAN/MDS-ES guideline establishes that invasive therapies should be considered when patients meet the "5-2-1" rule: oral levodopa 5 times daily, OFF symptoms ≥2 hours daily, and troublesome dyskinesia ≥1 hour daily 2.

For dyskinesia reduction specifically:

• GPi-DBS ranks highest with a standardized mean difference of -1.27 (95% CI: -1.65 to -0.88) and SUCRA score of 97.4% in network meta-analysis 1
• STN-DBS is also highly effective (SUCRA 89%) with the added benefit of allowing significant levodopa dose reduction 2
• Target selection algorithm:
  • If primary goal is dyskinesia reduction WITHOUT medication reduction → Choose GPi-DBS 3
  • If medication reduction is desired → Choose STN-DBS 3
  • If cognitive concerns exist (processing speed, working memory) → Favor GPi over STN 3
  • If depression risk is significant → Favor GPi over STN 3

Both targets show sustained efficacy beyond 15 years for STN and 8 years for GPi 2.

Device-Aided Therapies

Levodopa-carbidopa intestinal gel (LCIG) demonstrates strong efficacy:

• Reduces UDysRS scores by -17.37 points versus -2.33 for optimized medical treatment (difference -15.05, p<0.0001) 4
• SUCRA ranking of 89.7% in network meta-analysis 1
• Sustained benefit at 2-3 years in registry data 2

Continuous subcutaneous apomorphine (CAI) shows moderate improvement in on-time without troublesome dyskinesia over 12 weeks 2.

Oral Medications

Amantadine extended-release (ADS-5102/GOCOVRI™):

• Highest-ranking oral medication (SUCRA 86.5%) 1
• Reduces dyskinesia by -10.1 points on UDysRS versus placebo at 12 weeks (p<0.0001) 5
• Effect sustained from week 2 through 12 weeks 5
• Common adverse events: hallucinations, dizziness, dry mouth, peripheral edema, orthostatic hypotension 5

Immediate-release amantadine also shows efficacy (SUCRA 86.5%) but with less robust evidence 1.

Emerging Therapies

Mesdopetam (dopamine D3 antagonist) showed clinically meaningful improvement in modified UDysRS in phase 2b trials, though it failed the primary endpoint of Good ON-time 6. Further investigation is warranted at 7.5 mg twice daily dosing.

Clinical Algorithm

1. Assess severity: Use the "5-2-1" rule to identify candidates for invasive therapy 2
2. Optimize oral therapy first: Trial amantadine extended-release if not contraindicated 1, 5
3. For advanced disease with ≥1 hour troublesome dyskinesia daily:
   • Surgical candidate with no cognitive/mood concerns + desire for medication reduction → STN-DBS 3
   • Surgical candidate with cognitive concerns OR primary goal is dyskinesia reduction → GPi-DBS 3, 1
   • Not a surgical candidate → LCIG or continuous apomorphine 2, 4

Critical Pitfalls

• Do not confuse OFF-time symptoms with dyskinesia—they require opposite management strategies
• GPi-DBS does not allow significant levodopa reduction unlike STN-DBS 2
• Amantadine extended-release has higher adverse event rates than placebo, particularly hallucinations in elderly patients 5
• Head-to-head comparisons between invasive therapies are lacking—rankings come from network meta-analysis 2

The strong correlation between dyskinesia severity and pain (r=0.47-0.63) means effective dyskinesia treatment also improves pain and quality of life 7.